Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty

Cardiovascular Revascularization Medicine

Volumn 10, Issue 3, 2009, Pages 156-161

  Bonello, Laurent ^a   de Labriolle, Axel ^a   Roy, Probal ^a   Steinberg, Daniel H ^a   Pinto Slottow, Tina L ^a   Xue, Zhenyi ^a   Kaneshige, Kimberly ^a   Torguson, Rebecca ^a   Suddath, William O ^a   Satler, Lowell F ^a   Kent, Kenneth M ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Antithrombotics; In hospital outcome; Percutaneous coronary intervention; ST elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; TICLOPIDINE; WARFARIN;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULANT THERAPY; AORTA BALLOON; ARTICLE; BALLOON DILATATION; BLEEDING; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEMATOCRIT; HEMATOMA; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; SIDE EFFECT; ST SEGMENT ELEVATION; STENT THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HEART DISEASES; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; INTRA-AORTIC BALLOON PUMPING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649962911     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2008.12.005     Document Type: Article

References (18)

1. Kinnaird T.D., Stabile E., Mintz G.S., Lee C.W., Canos D.A., Gevorkian N., Pinnow E.E., Kent K.M., Pichard A.D., Satler L.F., Weissman N.J., Lindsay J., and Fuchs S. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
2. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
3. Rao S.V., Eikelboom J.A., Granger C.B., Harrington R.A., Califf R.M., and Bassand J.P. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1193-1204
4. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., Keren G., Carr J., Cohen E.A., Betriu A., Desmet W., Kereiakes D.J., Rutsch W., Wilcox R.G., de Feyter P.J., Vahanian A., Topol E.J., and REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
5. Stone G.W., Ware J.H., Bertrand M.E., Lincoff A.M., Moses J.W., Ohman E.M., White H.D., Feit F., Colombo A., McLaurin B.T., Cox D.A., Manoukian S.V., Fahy M., Clayton T.C., Mehran R., Pocock S.J., and ACUITY Investigators. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 298 (2007) 2497-2506
6. Stone G., and for the Horizon STEMI investigators. A prospective, randomized comparison of bivalirudin vs. heparin plus glycoprotein IIb/IIIa inhibitors during primary angioplasty in acute myocardial infarction angioplasty infarction - 30 day results. Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2007, Washington, DC (2007)
7. Kastrati A., Mehilli J., Neumann F.J., Dotzer F., ten Berg J., Bollwein H., Graf I., Ibrahim M., Pache J., Seyfarth M., Schühlen H., Dirschinger J., Berger P.B., Schömig A., and Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
8. Montalescot G., Antoniucci D., Kastrati A., Neumann F.J., Borentain M., Migliorini A., Boutron C., Collet J.P., and Vicaut E. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 28 (2007) 443-449
9. Steg P.G., Goldberg R.J., Gore J.M., Fox K.A., Eagle K.A., Flather M.D., Sadiq I., Kasper R., Rushton-Mellor S.K., Anderson F.A., and GRACE Investigators. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 90 (2002) 358-363
10. Hanania G., Cambou J.P., Guéret P., Vaur L., Blanchard D., Lablanche J.M., Boutalbi Y., Humbert R., Clerson P., Genès N., Danchin N., and USIC 2000 Investigators. Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart 90 (2004) 1404-1410
11. Abbott J.D., Ahmed H.N., Vlachos H.A., Selzer F., and Williams D.O. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute DynSTEMIc Registry). Am J Cardiol 100 (2007) 190-195
12. Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M., Hochman J.S., Krumholz H.M., Kushner F.G., Lamas G.A., Mullany C.J., Ornato J.P., Pearle D.L., Sloan M.A., Smith Jr. S.C., Alpert J.S., Anderson J.L., Faxon D.P., Fuster V., Gibbons R.J., Gregoratos G., Halperin J.L., Hiratzka L.F., Hunt S.A., Jacobs A.K., American College of Cardiology, American Heart Association Task Force on Practice Guidelines, and Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 110 (2004) e82-e292
13. Tolleson T.R., O'Shea J.C., Bittl J.A., Hillegass W.B., Williams K.A., Levine G., Harrington R.A., and Tcheng J.E. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 41 (2003) 386-393
14. Garattini S., and Bertele' V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 370 (2007) 1875-1877
15. Aggarwal A., Sobel B.E., and Schneider D.J. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 13 (2002) 161-165
16. Anand S.X., Kim M.C., Kamran M., Sharma S.K., Kini A.S., Fareed J., Hoppensteadt D.A., Carbon F., Cavusoglu E., Varon D., Viles-Gonzalez J.F., Badimon J.J., and Marmur J.D. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 100 (2007) 417-424
17. Lincoff A.M., Bittl J.A., Kleiman N.S., Sarembock I.J., Jackman J.D., Mehta S., Tannenbaum M.A., Niederman A.L., Bachinsky W.B., Tift-Mann III J., Parker H.G., Kereiakes D.J., Harrington R.A., Feit F., Maierson E.S., Chew D.P., Topol E.J., and REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93 (2004) 1092-1096
18. Chu W.W., Kuchulakanti P.K., Torguson R., Wang B., Clavijo L.C., Suddath W.O., Pichard A.D., Satler L.F., Kent K.M., and Waksman R. Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction. Cardiovasc Revasc Med 7 (2006) 132-135